Axonics Modulation Technologies (AXNX) vs. NuVasive (NUVA) Head to Head Review

Share on StockTwits

Axonics Modulation Technologies (NASDAQ:AXNX) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Axonics Modulation Technologies and NuVasive’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Axonics Modulation Technologies N/A N/A N/A
NuVasive 1.13% 14.60% 6.90%

Valuation and Earnings

This table compares Axonics Modulation Technologies and NuVasive’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Axonics Modulation Technologies $710,000.00 901.50 -$32.48 million ($4.64) -4.95
NuVasive $1.10 billion 2.67 $12.47 million $2.23 25.52

NuVasive has higher revenue and earnings than Axonics Modulation Technologies. Axonics Modulation Technologies is trading at a lower price-to-earnings ratio than NuVasive, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

31.9% of Axonics Modulation Technologies shares are held by institutional investors. 1.0% of NuVasive shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Axonics Modulation Technologies and NuVasive, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axonics Modulation Technologies 0 0 4 0 3.00
NuVasive 2 7 7 0 2.31

Axonics Modulation Technologies currently has a consensus target price of $21.48, indicating a potential downside of 6.57%. NuVasive has a consensus target price of $65.33, indicating a potential upside of 14.82%. Given NuVasive’s higher probable upside, analysts clearly believe NuVasive is more favorable than Axonics Modulation Technologies.

Summary

NuVasive beats Axonics Modulation Technologies on 10 of the 13 factors compared between the two stocks.

Axonics Modulation Technologies Company Profile

Axonics Modulation Technologies, Inc., a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was incorporated in 2012 and is based in Irvine, California.

NuVasive Company Profile

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine to perform restorative and fusion procedures in a minimally-disruptive fashion. The company's biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty and gel. Its IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, it offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Lindblad Expeditions Holdings Inc  Expected to Announce Earnings of $0.23 Per Share
Lindblad Expeditions Holdings Inc Expected to Announce Earnings of $0.23 Per Share
Bytom  Hits One Day Volume of $6.00 Million
Bytom Hits One Day Volume of $6.00 Million
Alt.Estate token Price Down 6.6% Over Last 7 Days
Alt.Estate token Price Down 6.6% Over Last 7 Days
Bitcore Price Reaches $0.46 on Top Exchanges
Bitcore Price Reaches $0.46 on Top Exchanges
40,494 Shares in iShares Core 1-5 Year USD Bond ETF  Purchased by PDS Planning Inc
40,494 Shares in iShares Core 1-5 Year USD Bond ETF Purchased by PDS Planning Inc
MediciNova, Inc.  Given Consensus Recommendation of “Strong Buy” by Brokerages
MediciNova, Inc. Given Consensus Recommendation of “Strong Buy” by Brokerages


© 2006-2019 Ticker Report